KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Research & Development: 2009-2024

Historic Research & Development for Arbutus Biopharma (ABUS) over the last 16 years, with Dec 2024 value amounting to $54.0 million.

  • Arbutus Biopharma's Research & Development fell 59.52% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.0 million, marking a year-over-year decrease of 53.74%. This contributed to the annual value of $54.0 million for FY2024, which is 26.68% down from last year.
  • Per Arbutus Biopharma's latest filing, its Research & Development stood at $54.0 million for FY2024, which was down 26.68% from $73.7 million recorded in FY2023.
  • Over the past 5 years, Arbutus Biopharma's Research & Development peaked at $84.4 million during FY2022, and registered a low of $49.3 million during FY2020.
  • Over the past 3 years, Arbutus Biopharma's median Research & Development value was $73.7 million (recorded in 2023), while the average stood at $70.7 million.
  • In the last 5 years, Arbutus Biopharma's Research & Development surged by 32.76% in 2021 and then decreased by 26.68% in 2024.
  • Over the past 5 years, Arbutus Biopharma's Research & Development (Yearly) stood at $49.3 million in 2020, then surged by 32.76% to $65.5 million in 2021, then climbed by 28.86% to $84.4 million in 2022, then fell by 12.69% to $73.7 million in 2023, then fell by 26.68% to $54.0 million in 2024.